DNA X, Inc. SONM
3.92
(0.03)
(0.76%)
as of 25 Sep
- Market cap
- $5.9M
- P/E
- 0.0×
Follow SONM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 666.17% | 1,433.07% | 302.56% | (455.82%) |
+8 more TTM periods Free account |
|
| (42.11%) | (72.43%) | (49.40%) | (74.71%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
383.79% | 1,451.38% | 95.12% | 396.72% | |
Average Days of Receivables |
0.00 | 0.00 | — | 82.37 | |
Free Cash Flow per Share |
(8.36) | (11.23) | (32.55) | (26.43) | |
Free Cash Flow |
(11.29) | (14.21) | (23.53) | (26.03) | |
Capital Expenditures |
3.21 | 3.17 | — | — | |
Piotroski F-Score |
— | — | 1.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
4,368.98% | (8,200.94%) | 353.67% | (1,543.95%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 5.02 | |
Accounts Payable Turnover |
0.00 | 0.00 | 7.85 | (0.01) | |
Inventory Turnover |
— | — | 0.00 | (0.01) | |
Average Days of Payables |
0.00 | 0.00 | 78.62 | (72,319.61) | |
Days of Inventory on Hand |
— | — | 0.00 | (38,930.97) | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.22) | |
Research and Development Expense of Revenue |
— | — | — | 25.77% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | (9.54%) | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 2.94% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.70 | 1.18 | 1.14 | 0.78 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 26.56 | |
Capex/Depreciation |
1.24 | 0.98 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 60.02 | |
Operating CF per Share |
(10.74) | (13.74) | (32.55) | (26.43) | |
Capex per Share |
2.38 | 2.51 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (56.48%) |
Columns are period end dates